Pubmed ID: 33945915
Publication Date: 2021/05/01
Rutaecarpine administration inhibits cancer cell growth in allogenic TRAMP-C1 prostate cancer mice correlating with immune balance in vivo.
Rutaecarpine (Rut) is a plant alkaloid abundant in Euodia ruticarpa which is a Chinese herbal medicine used for treating various cancers. However, the Rut administration effect on prostate cancer in vivo remains unclear.
In the present study we established an allogenic TRAMP-C1 prostate cancer mouse model to evaluate the Rut administration effect and mechanism in vivo.
To unravel the Rut administration effect on prostate cancer in vivo, C57BL/6J male mice (8 weeks old) were randomly grouped (nÂ =Â 9), subcutaneously loaded with TRAMP-C1 prostate cancer cells and immediately given daily by gavage with Rut dissolved in soybean oil at 7Â mg (low dose), 35Â mg (medium dose), and 70Â mg/kg b.w./day (high dose) for successive 39 days.
Rut administration significantly and dose-dependently reduced both tumor volume and solid prostate cancer weight in allogenic TRAMP-C1 male mice. Rut administration markedly increased (TNF-Î±+IFN-Î³) (Th1-)/IL-10 (Th2-) cytokine secretion ratios by splenocytes and TNF-Î± (M1-)/IL-10 (M2-) cytokine secretion ratios by macrophages as compared to those of dietary control group, suggesting that Rut administration in vivo regulates the immune balance toward Th1- and M1-polarized characteristics. Decreased CD19, CD4 and CD8 lymphocytes in the peripheral blood of allogenic TRAMP-C1 mice were significantly elevated by Rut administration. Tumor weights positively correlated with TNF-Î± secretions by splenocytes, suggesting that there is a tumor cachexia in the tumor-bearing mice. Tumor weights negatively correlated with IgG (Th1-antibody) levels in the sera, suggesting that Th1-polarized immune balance may inhibit prostate cancer cell growth.
Our results evidenced that Rut administration suppresses prostate cancer cell growth in mice subcutaneously loaded with TRAMP-C1 cells and correlated the anti-cancer effects with Th1-polarized immune balance in vivo.
Related products :
Homo sapiens,Human,Metalloreductase STEAP2,PCANAP1,Prostate cancer-associated protein 1,Protein upregulated in metastatic prostate cancer,PUMPCn,Six-transmembrane epithelial antigen of prostate 2,SixT
Erlotinib Erlotinib hydrochloride is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. For research use only.
C21orf33 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggests that growth inhibition induced in these cells by all-trans retinoic acid occurs via
Prostate Cancer Cell Lysate
PC-3 prostate cancer cell line: PC-3
||Flask or Vial